賽象科技(002337.SZ):收到孫雲權支付的部分股權轉讓款500萬元
格隆匯6月12日丨賽象科技(002337.SZ)公佈,2019年8月12日,天津賽象科技股份有限公司(以下簡稱“賽象科技”、“公司”)召開了第七屆董事會第二次會議,審議通過了轉讓參股公司廊坊智通機器人系統有限公司(以下簡稱“廊坊智通”)20.6161%的股權,轉讓價格為人民幣5669.3507萬元,受讓方為廊坊智通實際控制人、法定代表人孫雲權。轉讓完成後,公司仍持有廊坊智通5%股權,並按持股比例享受股東權益。
2020年6月12日,公司收到孫雲權支付的部分股權轉讓款500萬元,截至目前累計收到股權轉讓款1900萬元,公司將繼續推進後續付款事宜並敦促交易對方支付剩餘股權轉讓款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.